RVC and Maxwell Biotech Venture Fund Back Eleventa
Moscow-based Maxwell Biotech Venture Fund (MBVF), along with the Russian fund of funds RVC, has invested an undisclosed amount of money in the Russian biotech company Eleventa, which is trying to develop treatments for asthma and other allergic respiratory diseases.
4 October 2012•5 mins read
